Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02331290
Recruitment Status : Recruiting
First Posted : January 6, 2015
Last Update Posted : September 13, 2019
Sponsor:
Collaborator:
CancerCare Manitoba
Information provided by (Responsible Party):
University of Manitoba

Brief Summary:
This study is designed to determine if changes in acetyl amantadine (AA) metabolism with systemic chemotherapy - reflective of SSAT1 activity - are predictive of response to systemic therapy in patients with lung cancer. Ten patients with adenocarcinoma and 10 with small-cell cancer who are at American Joint Committee on Cancer (AJCC) stages 3 or 4 at the time of diagnosis will participate. AA metabolites will be examined by ELISA prior to initiation of systemic chemotherapy and after the second cycle of therapy. Changes in the pattern of metabolites will be correlated with convention clinical and radiographic response criteria.

Condition or disease
Lung Cancer

Detailed Description:

Evaluation of response to systemic therapy is dependant on clinical and radiographic changes assessed prior to and after several cycles of systemic therapy. The response rate for lung cancer to systemic therapy ranges from 30 - 85%, depending on histology and other clinical factors, but difficult to predict in individual patients. Spermine-spermidine acetyl transferase (SSAT1) activity is up-regulated in many cancers and may be a marker of response to therapy. Metabolism of acetyl amantadine (AA) is reflective of SSAT1 activity. In order to determine if change in SSAT1 activity is predictive of response to systemic chemotherapy, we propose the following pilot clinical trial. A total of 20 volunteer patients - 10 patients with adenocarcinoma of the lung and 10 patients with small-cell histology will be included. Eligibility includes patients with adenocarcinoma and small-cell lung cancer who are at AJCC stage III or IV at diagnosis. Volunteers will be informed that this study is examining the possibility that we can detect a therapeutic response by a change in their excretion of AA before it can be detected by conventional patient assessment methods. The chemotherapy regimen will be selected by the treating physician and will not be influenced by participation in this clinical trial. The usual treatment regimen for the entities described above is a platinum-based doublet, often cis-platin with etoposide or gemcitabine administered for 4 to 6 cycles. The therapeutic response rates with these drug regimens is about 40% for adenocarcinoma and 70% for small-cell carcinoma. Clinical response is usually assessed between the second and third cycles of chemotherapy.

Biological Sampling Details

Patient volunteers will be asked to fast overnight prior to the day of their first scheduled chemotherapy and to ingest an oral dose of 200 mg of amantadine hydrochloride (HCl) in the morning within an hour of arriving in clinic. The following biological specimens will be collected: blood (2 x 10 ml) at 2 and 4 hours after amantadine ingestion, saliva (2 x 5ml) immediately after the blood samples, and a total urine specimen between the time of the 2 blood samples. Patient will be instructed to empty the bladder immediately before the first blood sample and then collect the total urine produced until the end of the second blood sample (4 hours). Subsequently, the patient will be allowed lunch (if they so choose) prior to their scheduled chemotherapy.

The sampling protocol will be repeated 3 weeks later with the second cycle of chemotherapy.

Data to be collected: tumour type (histology), stage of cancer, age, sex, weight, height, smoking history, concurrent medications, systemic chemotherapy treatment prescribed and history of recent alcohol intake. Data will be used for correlation and to determine the relationship of plasma, salivary or urinary AA to the particular cancer diagnosis and response to treatment.

Primary Endpoints:

Documentation of acetylamantadine metabolite excretion/secretion.

Response to therapy (complete response, partial response, stable disease, progressive disease).

Time to disease recurrence or progression.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen
Actual Study Start Date : May 2016
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Group/Cohort
All patients
20 newly diagnosed patients with small-cell lung cancer and adenocarcinoma of the lung stage III or IV



Primary Outcome Measures :
  1. Pattern of AA metabolite excretion/secretion relative to response to therapy. [ Time Frame: Two months ]
    Correlation of AA metabolite excretion/secretion to response to systemic chemotherapy.


Secondary Outcome Measures :
  1. Pattern of AA metabolite excretion/secretion relative to time to recurrence or progression. [ Time Frame: Two years ]
    Correlation of AA metabolite excretion/secretion to time to disease recurrence or progression.


Biospecimen Retention:   Samples Without DNA

Blood (2 x 10 ml) at 2 and 4 hours after amantadine ingestion. Saliva (2 x 5ml) immediately after the blood samples. Urine specimen between the time of the 2 blood samples.

The sampling protocol will be repeated 3 weeks later with the second cycle of chemotherapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
20 patients: 10 patients with biopsy proven newly diagnosed Stage III or IV adenocarcinoma of the lung and 10 patients with Stage III or IV small-cell histology will be included.
Criteria

Inclusion Criteria:

  • Biopsy proven newly diagnosed advanced-stage small-cell lung cancer (SCLC) and adenocarcinoma of the lung being initiated on systemic chemotherapy.
  • Adequate hematological, renal and hepatic function sufficient to tolerate conventional doses of systemic chemotherapy.
  • Age > 18 years.
  • Measurable or evaluable disease by Response Evaluation Criteria in solid Tumors (RECIST) criteria.
  • Performance score < 3 (ECOG).
  • Capable of signing informed consent.

Exclusion Criteria:

  • Patients with significant liver and kidney disease, chronic drug therapy other then oral contraceptives. Pregnant or lactating female patients.
  • Women with childbearing potential must have a negative pregnancy test and be willing to use effective contraceptive techniques if sexually active.
  • Previous history of adverse reactions to amantadine.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02331290


Contacts
Layout table for location contacts
Contact: Andrew W Maksymiuk, MD FRCP(C) (204) 787-2021 amaksymiuk@cancercare.mb.ca
Contact: Daniel S. Sitar, PhD (204) 789-3532 sitar@ms.umanitoba.ca

Locations
Layout table for location information
Canada, Manitoba
St. Boniface Hospital Recruiting
Winnipeg, Manitoba, Canada, R2H 2A6
Contact: Paramjit S Tappia, PhD    204-258-1230    ptappia@sbrc.ca   
Contact: Andrew Maksymiuk, MD    204-7871884    amaksymiuk@cancercare.mb.ca   
CancerCare Manitoba Not yet recruiting
Winnipeg, Manitoba, Canada, R3E 0V9
Contact: Andrew W Maksymiuk, MD FRCP(C)    (204) 787-2021    amaksymiuk@cancercare.mb.ca   
Contact: Daniel S Sitar, PhD    (204) 789-3532    sitar@ms.umanitoba.ca   
Sponsors and Collaborators
University of Manitoba
CancerCare Manitoba
Investigators
Layout table for investigator information
Principal Investigator: Andrew W Maksymiuk, MD FRCP(C) CancerCare Manitoba

Publications:
Layout table for additonal information
Responsible Party: University of Manitoba
ClinicalTrials.gov Identifier: NCT02331290     History of Changes
Other Study ID Numbers: RRIC 2014-047
First Posted: January 6, 2015    Key Record Dates
Last Update Posted: September 13, 2019
Last Verified: May 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases